CPHI 2022: Bioiberica to spotlight pharma-nutra ingredients for tomorrow’s health solutions
17 Oct 2022 --- Bioiberica is set to demonstrate innovations for a healthier life through its complete pharma-nutra ingredient portfolio at CPHI 2022 in Frankfurt, Germany (November 1-3). Its combined offering of biologically-derived active pharmaceutical ingredients (APIs) and branded ingredients enables manufacturers to bolster their offering, paving the way for “the health solutions of tomorrow.”
The company is a leading heparin manufacturer and world reference in the research, development and production of biologically-derived APIs. Its nutraceutical-branded ingredients will be offered for the first time at CPHI Worldwide 2022, a world-leading pharmaceutical and nutrition trade show.
Blending pharma and nutraceutical
The new ingredients reflect a key turning point in the healthcare industry’s ongoing evolution, the company says, where the lines between the pharmaceutical and nutraceutical spaces are becoming increasingly blurred.
Experts from the company will be at stand 121A10 to highlight how its combined portfolio of pharmaceutical APIs and scientifically-backed branded ingredients, together with the benefits of a vertically integrated global supply chain, can help manufacturers respond to some of the world’s toughest healthcare challenges.
“In recent years, we’ve noted a growing appetite from pharmaceutical companies to explore new strategic partnerships which enable the development of nutraceutical formulations that enhance their long-standing pharmaceutical product offering,” says Luis Solera, CEO at Bioiberica
Experts from Bioiberica’s Heparin Science business unit will be available to discuss the latest heparin developments at CPHI 2022..
“At this year’s edition of CPHI, we’re excited to show pharmaceutical manufacturers how our wider healthcare portfolio can help them do just that – delivering essential drugs while also catering to the latest consumer health trends, such as the growing demand for naturally-derived ingredients.”
Changes in the heparin market
On its stand, experts from Bioiberica’s Heparin Science business unit will be available to discuss the latest market developments and changing regulatory environment impacting the heparin market – most commonly used as an anti-coagulant drug that reportedly saves more than 100 million lives globally every year.
The Bioiberica Healthcare team will also be showcasing its established range of APIs – Chondroitin Sulfate for the symptomatic treatment of osteoarthritis, Glucosamine for the symptomatic treatment of mild knee osteoarthritis and Thyroid for endocrinology, alongside its flagship branded ingredients for mobility, (Collavant n2 – native (undenatured) type II collagen and Mobilee – hyaluronic acid matrix ingredient), digestive health (DAOgest – diamine oxidase enzyme) and skin & beauty (Dermial – hyaluronic acid matrix ingredient).
We recently discussed these solutions in more detail ahead of the SupplySide West trade show in Las Vegas, US.
“The world of healthcare is evolving at pace, so for manufacturers to succeed, they need to keep up with what really matters to consumers,” adds Joan Bassa Camps, human health director at Bioiberica.
“We’re on a mission to meet like-minded businesses who are passionate about improving people’s health – and CPHI provides us with the perfect platform to do this. We’re proactively seeking strategic partnerships with forward-thinking companies looking to create cutting-edge formulations that meet today’s evolving health needs.”
“From developing new APIs to providing pilot manufacturing or scale-up services, we offer a vast range of experience and expertise that can help pharmaceutical companies realize health solutions that have the power to transform lives.”
Edited by Joshua Poole
